Apremilast

阿普米司特

Report date: 2026/05/15 20:01:45
NMEFirst In Class

Base Information

Drug NameApremilast
Drug Alias Name阿普司特apremilast阿普米司特apremilastum阿普斯特 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodieterase 4 inhibitors
TargetsPhosphodieterase 4
Therapy Area/IndicationsPlaque psoriasisCoronavirus Disease 2019 (COVID-19)Palmoplantar pustulosis +[34] 
Global Approved IndicationsPlaque psoriasisPsoriasisArthritis, Psoriatic
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryUnited States
Original Approved Date2014/03/21
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesHumanis Saglık Anonim SirketiYale UniversityTufts Medical Center Inc +[8] 
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgOregon Health And Science UniversityWake Forest University Health Sciences +[18] 
Active IndicationsPlaque psoriasisCoronavirus Disease 2019 (COVID-19)Palmoplantar pustulosis +[14] 
Inactive IndicationsPrurigo NodularisRosaceaPruritus +[20] 

Other Information

ATC CodeL04AA32
Related LinksWikipediaDrugBankKEGG